المؤلفون: Gul, Anita, Stewart, Tyler F, Mantia, Charlene M, Shah, Neil J, Gatof, Emily Stern, Long, Ying, Allman, Kimberly D, Ornstein, Moshe C, Hammers, Hans J, McDermott, David F, Atkins, Michael B, Hurwitz, Michael, Rini, Brian I

المصدر: Journal of Clinical Oncology. 38(27)

مصطلحات موضوعية: Kidney Disease, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Renal Cell, Disease Progression, Female, Humans, Immune Checkpoint Inhibitors, Ipilimumab, Kidney Neoplasms, Male, Middle Aged, Nivolumab, Programmed Cell Death 1 Receptor, Progression-Free Survival, Retreatment, Retrospective Studies, Salvage Therapy, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis

الوصف: PurposeImmune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy.Patients and methodsPatients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed.ResultsForty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients.ConclusionIpilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5n52s9tpTest

المؤلفون: Gul, Anita, Alberty-Oller, J Jaime, Sandhu, Jagbir, Ayala-Bustamante, Everick, Adams, Sylvia

المصدر: NYMC Faculty Publications

مصطلحات موضوعية: Faculty, Medicine and Health Sciences

العلاقة: https://touroscholar.touro.edu/nymc_fac_pubs/4337Test; https://pubmed.ncbi.nlm.nih.gov/37196220/?myncbishare=nymclibTest

الإتاحة: https://doi.org/10.1200/PO.22.00506Test
https://touroscholar.touro.edu/nymc_fac_pubs/4337Test
https://pubmed.ncbi.nlm.nih.gov/37196220/?myncbishare=nymclibTest

المؤلفون: Gul, Anita, Rini, Brian I.

المصدر: Cancer ; volume 125, issue 17, page 2935-2944 ; ISSN 0008-543X 1097-0142

الوصف: Localized renal cell carcinoma (RCC) has an associated risk of recurrence after nephrectomy. Several clinical risk models attempt to predict oncologic outcomes based on clinical and pathologic features. In addition, novel gene signatures have been developed to refine risk prediction based on tumor biology. Systemic therapies targeting angiogenic pathways that are effective in metastatic RCC failed to show an improvement in overall survival in the adjuvant setting. Immune checkpoint inhibitors have shown significant antitumor activity with prolonged and durable responses in metastatic RCC, which led to an interest in evaluating these agents in the adjuvant setting. In this review, clinical risk‐predictive models, novel gene signatures, major clinical trials completed in the adjuvant setting, ongoing immune checkpoint inhibitor trials, and the perspective of adjuvant treatment in RCC are discussed.

الإتاحة: https://doi.org/10.1002/cncr.32144Test

المؤلفون: Gul, Anita, Garcia, Jorge A., Barata, Pedro C.

المصدر: Cancer Management and Research ; volume Volume 11, page 7253-7262 ; ISSN 1179-1322

الإتاحة: https://doi.org/10.2147/cmar.s165706Test
https://www.dovepress.com/getfile.php?fileID=51705Test

المؤلفون: Koshkin, Vadim S., Mir, Maria C., Barata, Pedro, Gul, Anita, Gupta, Ruby, Stephenson, Andrew J., Kaouk, Jihad, Berglund, Ryan, Magi-Galluzzi, Cristina, Klein, Eric A., Dreicer, Robert, Garcia, Jorge A.

المصدر: Investigational New Drugs ; volume 37, issue 3, page 559-566 ; ISSN 0167-6997 1573-0646

مصطلحات موضوعية: Pharmacology (medical), Pharmacology, Oncology

الإتاحة: https://doi.org/10.1007/s10637-019-00778-4Test

المؤلفون: Gul,Anita, Garcia,Jorge A., Barata,Pedro C.

مصطلحات موضوعية: Cancer Management and Research

الوصف: Anita Gul,1 Jorge A Garcia,1 Pedro C Barata21Department of Hematology/Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; 2Tulane University, New Orleans, LA, USAAbstract: Androgen deprivation therapy (ADT) is an important component of systemic therapy in advanced prostate cancer; however, resistance to ADT is inevitable. Three large studies demonstrated the efficacy of novel androgen receptor (AR)-targeted therapies in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Enzalutamide and apalutamide have been approved by the FDA in the nmCRPC setting. This review discusses the role of AR and ADT in prostate cancer, mechanism of ADT resistance and the nmCRPC stage. In addition, pharmacologic characteristics and clinical development of apalutamide, role of apalutamide in nmCRPC, and ongoing clinical studies of apalutamide in different stages of prostate cancer are discussed.Keywords: androgen receptor, non-metastatic castration-resistant prostate cancer, apalutamide, ARN-509, Phase III trials

وصف الملف: text/html

العلاقة: https://www.dovepress.com/treatment-of-non-metastatic-castration-resistant-prostate-cancer-focus-peer-reviewed-fulltext-article-CMARTest

الإتاحة: https://doi.org/10.2147/CMAR.S165706Test
https://www.dovepress.com/treatment-of-non-metastatic-castration-resistant-prostate-cancer-focus-peer-reviewed-fulltext-article-CMARTest